Use of neoadjuvant chemotherapy prior to radical hysterectomy in cervical cancer: Monitoring tumour shrinkage and molecular profile on magnetic resonance and assessment of 3-year outcome

British Journal of Cancer

Volumn 90, Issue 12, 2004, Pages 2326-2331

  DeSouza, N M ^a,c   Soutter, W P ^a   Rustin, G ^b   Mahon, M M ^a   Jones, B ^a   Dina, R ^a   McIndoe, G A ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cervical cancer; Magnetic resonance imaging; Magnetic resonance spectroscopy; Neoadjuvant chemotherapy; Outcome

Indexed keywords

BLEOMYCIN; CISPLATIN; FOLINIC ACID; METHOTREXATE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; RANDOMIZATION; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TUMOR VOLUME; UTERINE CERVIX CANCER; ADJUVANT THERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; HYSTERECTOMY; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; SURVIVAL; TREATMENT OUTCOME; UTERINE CERVIX TUMOR;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; FEMALE; HUMANS; HYSTERECTOMY; LEUCOVORIN; MAGNETIC RESONANCE IMAGING; METHOTREXATE; MIDDLE AGED; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 3042737825     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601870     Document Type: Article

References (27)

1. Aoki Y, Tomita M, Sato T, Watanabe M, Kase H, Fujita K, Kurata H, Tanaka K (2001) Neoadjuvant chemotherapy for patients younger than 50 y with high-risk squamous cell carcinoma of the cervix. Gynecol Oncol 83: 263-267
2. Benedetti-Panici P, Greggi S, Scambia G, Amoroso M, Salerno MG, Maneschi F, Cutillo G, Paratore MP, Scorpiglione N, Mancuso S (1998) Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Eur J Cancer 34: 341-346
3. Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F, Zola P, Mangioni C, Landoni F (2002) Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multi-center randomized trial. J Clin Oncol 20: 179-188
4. Benedetti-Panici P, Scambia G, Baiocchi G, Gregi S, Ragusa G, Gallo A, Conte M, Battaglia F, Laurelli G, Rabitti C, Capelli A, Mancuso S (1991) Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer: prognostic factors for response and survival. Cancer 67: 372-379
5. Blankenberg FG, Katsikis PD, Storrs RW, Beaulieu C, Spielman D, Chen JY, Naumovski L, Tait JF (1997) Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood 89: 3778-3786
6. Chang TC, Lai CH, Hong JH, Hsueh S, Huang KG, Chou HH, Tseng CJ, Tsai CS, Chang JT, Lin CT, Chang HH, Chao PJ, Ng KK, Tang SG, Soong YK (2000) Randomized trial of neoadjuvant cisplatin, bleomycin and radical hysterectomy versus radiation therapy for bulky stage Ib and IIa cervical cancer. J Clin Oncol 18: 1740-1747
7. Costa S, Terzano P, Santini D, Ceccarelli C, Martoni A, Angelelli B, Panetta A, Bovicelli A, Cristiani P, Lipponen P, Erzen M, Syrjanen S, Syrjanen K (2001) Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis, and proliferation as determinants of response to therapy and disease outcome. Am J Clin Pathol 116: 729-737
8. Delikatny EJ, Russell P, Hunter JC, Hancock R, Atkinson KH, van Haaften-Day C, Mountford CE (1993) Proton MR and human cervical neoplasia: ex. vivo spectroscopy allows distinction of invasive carcinoma of the cervix from carcinoma in situ and other preinvasive lesions. Radiology 188: 791-796
9. deSouza NM, Scoones D, Krausz T, Gilderdale DJ, Soutter WP (1996) High resolution MR imaging of Stage I cervical neoplasia with a dedicated transvaginal coil: MR features and correlation of imaging and pathological findings. Am J Roentgenol 166: 553-559
10. deSouza NM, Whittle M, Williams AD, Soheil M, Krausz T, Gilderdale DJ, McIndoe GA, Soutter WP (2000) Magnetic resonance imaging of the primary site in Stage I cervical carcinoma: a comparison of endovaginal and external phased array techniques at 0.5-T. J Magn Reson Imaging 12: 1020-1026
11. Eddy GL, Manetta A, Alvarez RD, Williams L, Creasman WT (1995) Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO Stage Ib bulky cervical cancer: a Gynecologic Oncology Group pilot study. Gynecol Oncol 57: 412-416
12. Eifel PJ (2000) Chemoradiation for carcinoma of the cervix: advances and opportunities. Radiat Res 154: 229-236
13. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, Williams CJ (2001) Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358: 781-786
14. Hwang YY, Moon H, Cho SH, Kim KT, Moon YJ, Kim SR, Kim DS (2001) Ten-year survival of patients with locally advanced Stage Ib-IIb cervical cancer after neoadjuvant chemotherapy and radical hysterectomy. Gynecol Oncol 82: 88-93
15. 1H MR spectroscopy. NMR Biomed 7: 172-180
16. 1H MRS of high-grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed 7: 149-155
17. 3) spatial resolution. Radiology 198: 795-805
18. Kvistad KA, Bakken IJ, Gribbestad IS, Ehrnholm B, Lundgren S, Fjosne HE, Haraldseth O (1999) Characterisation of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging 10: 159-164
19. Lai CH, Hsueh S, Chang TC, Tseng CJ, Huang KG, Chou HH, Chen SM, Chang MF, Shum HC (1997) Prognostic factors in patients with bulky stage Ib or IIa cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomy. Gynecol Oncol 64: 456-462
20. Le Moyec L, Tatoud R, Eugene M, Gauville C, Primot I, Charlemagne D, Calvo F (1992) Cell and membrane lipid analysis by proton magnetic resonance spectroscopy in five breast cancer cell lines. Br J Cancer 66: 623-628
21. 1H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration. NMR Biomed 17: 1-9
22. Negendank W, Sauter R (1996) Intratumoural lipids in 1 H MRS in vivo in brain tumours: experience of the Siemens cooperative clinical trial. Anticancer Res 16: 1533-1538
23. Paladini D, Raspagliesi F, Fontanelli R, Ntousias V (1995) Radical surgery after induction chemotherapy in locally advanced cervical cancer; a feasibility study. Int J Gynecol Cancer 5: 296-300
24. Sardi JE, Giaroli A, Sananes C, Ferreira M, Soderini A, Bermudez A, Snaidas L, Vighi S, Gomez Rueda N, Paola G (1997) Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in Stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol 67: 61-69
25. Soutter WP, Hanoch J, Gornall RJ, McIndoe GA, deSouza NM. Pretreatment tumour volume in cervical cancer as a predictor of survival: assessment using endovaginal and external coil magnetic resonance imaging. Br J Obstet Gynaecol, (in press)
26. Vigneron D, Bollen A, McDermott M, Wald L, Day M, Moyher-Noworolski S, Henry R, Chang S, Berger M, Dillon W, Nelson S (2001) Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumours. Magn Reson Imaging 19: 89-101
27. Wagenaar HC, Trimbos JB, Postema S, Anastasopoulou A, van der Geest RJ, Reiber JH, Renter GG, Peters AA, Pattynama PM (2000) Tumor diameter and volume assessed by magnetic resonance imaging in the prediction of outcome for invasive cervical cancer. Gynecol Oncol 82: 474-482